Genprex Advances Cancer Trials and Diabetes Therapy [Yahoo! Finance]
Genprex, Inc. (GNPX)
Last genprex, inc. earnings: 11/14 12:08 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Genprex ( (GNPX) ) has issued an announcement. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Genprex has provided updates on its clinical trials and diabetes gene therapy programs. The Acclaim-1 and Acclaim-3 clinical trials, which focus on different types of lung cancer, have received FDA Fast Track and Orphan Drug Designations, reflecting their potential significance in cancer treatment. Additionally, the company is progressing with its diabetes gene therapy program, currently in preclinical evaluation at the University of Pittsburgh, with plans to advance regulatory discussions in 2025. More abo
Read more
Impact Snapshot
Event Time:
GNPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc. news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerPR Newswire
- Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare ConferencePR Newswire
- Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerPR Newswire
- Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer [Yahoo! Finance]Yahoo! Finance
GNPX
Sec Filings
- 1/23/25 - Form 8-K
- 1/15/25 - Form SCHEDULE
- 1/13/25 - Form 8-K
- GNPX's page on the SEC website